Emivirine

DRUG5 trials

Sponsors

Triangle Pharmaceuticals, Bristol-Myers Squibb

Conditions

HIV Infections

Phase 2

A Study of MKC-442 in Combination With Other Anti-HIV Drugs

CompletedNCT00002412

Triangle PharmaceuticalsHIV Infections

Updated: 2005-06-24

A Study of MKC-442 in HIV-Positive Patients

CompletedNCT00002413

Triangle PharmaceuticalsHIV Infections

Updated: 2005-06-24

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

TerminatedNCT00002420

Bristol-Myers SquibbHIV Infections

Target: 25Updated: 2008-08-14

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

TerminatedNCT00002418

Bristol-Myers SquibbHIV Infections

Target: 25Updated: 2008-08-14

Unknown Phase

A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive

CompletedNCT00002215

Triangle PharmaceuticalsHIV Infections

Updated: 2005-06-24